Marcella fasso
WebApr 2, 2012 · IL-15 is critically important for development and homeostasis of memory CD8 T cells, natural killer (NK) cells, NK T cells, and intraepithelial lymphocytes (1 –3).Compared with IL-2, IL-15 favors survival of NK and memory phenotype CD8 T cells without side effects of IL-2, such as expansion of regulatory T cells (Tregs) or induction of activation-induced … WebMarcella Fassò's 5 research works with 443 citations and 660 reads, including: CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
Marcella fasso
Did you know?
WebFeb 26, 2024 · 187 Background: In the past decade, several therapies have been approved for mCRPC. However, most pts develop resistance and experience disease progression. Thus, there remains a high unmet need. Atezo (anti–PD-L1) blocks the interaction between PD-L1 and its receptors, PD-1 and B7.1, thereby restoring anti-tumor immunity. Atezo … WebMay 15, 2024 · M. Fasso is an employee for Genentech, and reports receiving commercial research grants from F. Hoffmann-La Roche. C. O'Hear is an employee for Genentech, Inc., and holds ownership interest (including patents) in Roche. B. Wu is an employee for Genentech/Roche. Acknowledgments
WebSep 29, 2024 · Marcella Fasso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already … WebJan 15, 2012 · Abstract. Thermal ablation to destroy tumor tissue may help activate tumor-specific T cells by elevating the presentation of tumor antigens to the immune system. However, the antitumor activity of these T cells may be restrained by their expression of the inhibitory T-cell coreceptor CTLA-4, the target of the recently U.S. Food and Drug ...
WebMarcella Fassò's research while affiliated with University of California, San Francisco and other places Overview What is this page? This page lists the scientific contributions of an … WebMar 4, 2008 · Discovery of immunologically relevant antigens in prostate cancer forms the basis for developing more potent active immunotherapy. We report here a strategy using the transgenic adenocarcinoma of mouse prostate (TRAMP) model, which allows for the functional identification of immunogenic prostate tum …
WebMost widely held works by Marcella Fassò Analysis of the CD4+ T cell immune response in vivo using CD4 up-regulation as an activation marker : normal versus autoimmune …
WebApr 15, 2013 · We formulated CDN with a GM-CSF secreting tumor cell vaccine (STINGVAX) to mobilize and as well as activate dendritic cells both in vitro and in vivo. … healthware systemsWebJan 11, 2016 · , Marcella Fassò , Yan V. Wang , Wei Zou , Priti S. Hegde , Gregg D. Fine , Thomas Powles Show More Abstract Full Text PDF Figures and Tables Supplements Abstract Purpose The objective was to determine the safety and clinical activity of atezolizumab (MPDL3280A), a humanized programmed death-ligand 1 (PD-L1) antibody, … healthware systems supportWebMarcella Fasso is 52 years old and was born on 10/01/1970. Previous to Marcella's current city of Richmond, CA, Marcella Fasso lived in Oakland CA and Palo Alto CA. Personal details about Marcella include: political affiliation is unknown; ethnicity is Caucasian; and religious views are listed as Christian. We know that Marcella is married at ... good games coming to ps4WebMay 20, 2016 · 11506 Background: Atezolizumab (atezo, MPDL3280A) is a humanized IgG1 mAb that prevents the interaction of the ligand PD-L1 with PD-1 and B7.1 and can reinvigorate anticancer T-cell responses. Atezo does not inhibit the interaction of an alternative ligand PD-L2 with PD-1. PD-L2 is associated with Th2 immune responses but … good games 2022 freeWebNov 4, 2015 · Marcella Fasso, Priti Hegde & Sanjeev Mariathasan Journal for ImmunoTherapy of Cancer 3, Article number: P83 ( 2015 ) Cite this article 1260 Accesses 9 Citations 3 Altmetric Metrics Atezolizumab (anti-PD-L1) has demonstrated robust clinical activity in UBC [ 1 ]. healthware srlWebMarcella Fasso,1,7 Ravi Sachidanandam,5 Anitha Jayaprakash,5 Ingrid Lin,1,2 Amy-Jo Casbon,1,8 Gillian A. Kinsbury,3,9 and Lawrence Fong1 ,2 10 * 1Department of Hematology and Oncology, University of California, San Francisco, San Francisco, CA 94143, USA healthware travelWebApr 20, 2015 · Early data in a preliminary human study show that an experimental immune system drug is generally safe and well tolerated in women with metastatic, triple-negative breast cancer, a persistently ... healthware stationary bike